Prevalence of the factor V Leiden mutation in patients susceptible to venous thromboembolism

• Autorzy: Mitrus J.M. , Wierszylo E.

Warianty tytułu

PL

Częstość występowania mutacji czynnika V Leiden u pacjentów ze skłonnością do żylnej choroby zakrzepowo-zatorowej

• Języki publikacji: EN

Abstrakty

EN

Background. A tendency to venous thromboembolism is otherwise called hypercoagulability or thrombophilia. This disease can be acquired or have a genetic background, and may lead to pulmonary embolism. The basis for analysis and selection of treatment is genetic diagnosis, which detects the G1691A mutation in the factor V gene (factor V Leiden) – the best known congenital thrombophilia marker. Material and methods. The study was carried out in the years 2015-2017 on samples taken from patients (462 men and 1284 women) with a tendency to venous thromboembolism. Real-Time PCR was used to detect G1691A mutation in factor V gene. The analyses were performed in the Hematology Laboratory of the Center of Laboratory Medicine at the Medical University of Gdańsk. Results. Significant differences in the frequency of Leiden mutation were shown. This mutation predominated in men (25%), while in women G1691A mutation was detected with a 15% frequency (p=0.04). All possible genotypes were found among the subjects and the percentage of heterozygotes and homozygotes in both genders was similar. Conclusions. Congenital t hrombophilia a ssociated w ith G1691A mutation of f actor V Leiden gene was found to be more common in men than in women. All possible genotypes were determined in the pool of test subjects. The mutation was most frequently detected in patients between 30 and 40 years of age, and rarely after 70 years of age.

PL

Wprowadzenie. Nadkrzepliwość (trombofilia) jest to skłonność do żylnej choroby zakrzepowozatorowej. Choroba ta może być nabyta lub mieć podłoże genetyczne i może prowadzić do zatorowości płucnej. Podstawą analizy i doboru leczenia jest diagnostyka genetyczna. Celem tej diagnostyki jest wykrycie mutacji G1691A w genie czynnika V (czynnik V Leiden) – najlepiej poznanego markera trombofilii wrodzonej. Materiał i metody. Badania zostały przeprowadzone w latach 2015-2017 na próbkach pobranych od pacjentów (462 mężczyzn i 1284 kobiet) ze skłonnością do żylnej choroby zakrzepowozatorowej. W celu wykrycia mutacji G1691A w genie czynnika V zastosowano metodę Real-Time PCR. Analizy zostały wykonane w Laboratorium Hematologii Uniwersyteckiego Centrum Medycyny Laboratoryjnej przy Gdańskim Uniwersytecie Medycznym. Wyniki. Wykazano istotne statystycznie różnice w częstości występowania mutacji Leiden. Mutację częściej występowała w grupie mężczyzn (25%), zaś u kobiet mutację G1691A wykrywano z częstością 15% (p=0,04). Wśród osób badanych stwierdzono wszystkie możliwe genotypy, a procentowy udział heterozygot i homozygot u obu płci był zbliżony. Wnioski. Trombofilia wrodzona związana z mutacją G1691A w genie czynnika V Leiden częściej występowała u mężczyzn niż kobiet. W puli osób poddanych testom oznaczono wszystkie możliwe genotypy. Mutację najczęściej wykrywano u pacjentów w przedziale wiekowym 30-40 lat, a najrzadziej po 70 roku życia.

Słowa kluczowe

EN

prevalence; human disease; hypercoagulability; V Leiden mutation; patient; venous thromboembolism; factor V Leiden; real-time polymerase chain reaction; genotyping method

• Wydawca: -
• Czasopismo: Health Problems of Civilization
• Rocznik: 2020
• Tom: 14
• Numer: 2
• Opis fizyczny: p.83-93,fig.,ref.

Twórcy

autor

Mitrus J.M.

• University of Natural Sciences and Humanities in Siedlce, Siedlce, Poland

autor

Wierszylo E.

• Central Laboratory of University Clinical Center in Gdansk, Gdansk, Poland

Bibliografia

• 1. Jastrzębska M. [Laboratory diagnostics in homeostasis]. Warszawa: Oinpharma; 2009 (in Polish).
• 2. Windyga J. [Coagulation disorders in everyday medical practical practice. 1st edition]. Poznań: Termedia; 2017 (in Polish).
• 3. Cushmann M, Tsai AW, White RH. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. The American Journal of Medicine. 2004; 117(1): 19-25. https://doi.org/10.1016/j.amjmed.2004.01.018
• 4. Kozdrój B, Noszczyk W. [Venous thromboembolism – procedures in the practice of a general practitioner]. Przewodnik Lekarski. 2004; 4(7): 22-30 (in Polish).
• 5. Nordström M, Lindblad B, Berggvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. Journal of Internal Medicine. 1992; 232(2): 155-160. https://doi.org/10.1111/j.1365-2796.1992.tb00565.x
• 6. Odnoczko E, Baran B, Windyga J. [To be on first-name terms with homeostasis]. Grudziądz: Wyd. Bio-Ksel; 2016 (in Polish).
• 7. Wojtasińska E. [Inherited thrombophilia as a risk factor of venous thromboembolism] [dissertation]. Poznań: Poznan University of Medical Sciences; 2014 (in Polish).
• 8. Gutknecht P, Łuszczyńska-Nitka G, Siebert J. [Venous thromboembolism in the practice of a general practitioner]. Forum Medycyny Rodzinnej. 2007; 1(2): 115-124 (in Polish).
• 9. Nalewczyńska A, Maździarz A, Krynicki R, Śpiewankiewicz B. [Venous thromboembolism – epidemiology and prophylaxis]. Current Gynecologic Oncology. 2015; 13(3): 191-200 (in Polish).
• 10. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBO Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thrombosis and Haemostasis. 2000; 83(05): 657-660.
• 11. Undass A. [Thrombophilia states]. In: Gajewski P, Augustynowicz-Kopeć E., editors. [Interna Szczeklika: internal diseases handbook]. Kraków: Wydawnictwo Medycyna Praktyczna; 2013. p. 1768-1771 (in Polish).
• 12. Prandoni P, Vilalta S, Bagatella P, Rossi L, Marchiori A, Piccioli A, et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997; 82(4): 423-428.
• 13. Bałajewicz-Nowak M, Pityński K, Milewicz T. [The 1691 G > A (factor V Leiden) and 1328 T > C V coagulation factor polymorphisms and recurrent miscarriages]. Ginekologia Polska. 2015; 86, 46-52 (in Polish).
• 14. Emmerich J, Aiach M, Morange PM, Marder VJ, Aird WC, Bennett JS. Thrombophilia genetics. Haemostasis and thrombosis. Philadelphia: Lippincott Williams & Wilkins. 2013; 962- 972.
• 15. Zawilska K. [Hereditary thrombophilia and venous thromboembolism]. Hematologia. 2013; 4(1): 35-42 (in Polish).
• 16. Tsantes AE, Nikolopoulos G, Bagos PG, Banovas S, Kopterides P, Vaiopoulos G. The effect of the plasminogen activator inhibitor-PAI 1 4G/5G polimorphism on the thrombotic risk. Thrombosis Research. 2008; 122(6): 736-742. https://doi.org/10.1016/j.thromres.2007.09.005
• 17. Middeldorp S. Is thrombophilia testing useful?. Hematology ASH Education Program. 2011; 2011(1): 150-155. https://doi.org/10.1182/asheducation-2011.1.150
• 18. Ziółkowska S, Ziółkowski W, Mądra-Gackowska K, Żekanowska E, Kędziora-Kornatowska K. [Hemostatic disorders in the elderly]. Geriatria. 2018; 12: 104-109 (in Polish).
• 19. Bertina RM, Koeleman BP, Koster T. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994; 369: 64-67. https://doi.org/10.1038/369064a0
• 20. Press RD, Bauer KA, Kujovich JL, Heit JA. Clinical utility of factor V Leiden testing for diagnosis and management of thromboembolic disorders. The Archives of Pathology & Laboratory Medicine. 2002; 126(11): 1304-1318. https://doi.org/10.1043/0003-9985(2002)126<1304:CUOFVL>2.0.CO;2
• 21. Rajewski M. [The incidence of polymorphisms of factor V genes (G1691A) and prothrombin (G20210a) and antiphospholipid antibodies in women with pregnancy pathologies] [dissertation]. Poznań: Poznan University of Medical Sciences; 2009 (in Polish).
• 22. Press DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995; 346: 1133-1134.
• 23. Heit JA, Kobbervik CE, James AH, Petterson TM, Baile KR, Melton LJ. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30 year population-based study. Annals of Internal Medicine. 2005; 143(10): 697-706. https://doi.org/10.7326/0003-4819-143-10-200511150-00006
• 24. Many A, Elad R, Yaron Y, Eldor A, Lessing JB, Kupferminc MJ. Third-trimester intrauterine fetal death is associated with inherited thrombophilia. Obstetrics & Gynecology. 2002; 999(5/1): 684-687.
• 25. Sasson Z, Mangat I, Grande P, Lorrette I. Left atrial appendage thrombusinatrial flutter with no associated disease. Journal of the American Society Echocardiography. 1996; 9(5): 730-732.
• 26. Barlik M. [The evaluation of the correlation between polymorphisms of coagulation factor VII gene and tissue plasminogen activator inhibitor and recurrent miscarriages]. [dissertation]. Poznań: Poznan University of Medical Sciences; 2014 (in Polish).
• 27. Sikkema JM, Franx A, Bruinse HW, Nikkels PG. Placental pathology in early onset pre-eclampsia and intrauterine growth restriction in women with and without thrombophilia. Placenta. 2002; 23(4): 337-342. https://doi.org/10.1053/plac.2001.0785
• 28. Coriu L, Copaciu E, Tulbure D, Talmaci R, Secara D, Coriu D, et al. Inherited thrombophilia in pregnant women with intrauterine growth restriction. Maedica (Buchar). 2014; 9(4): 351-355.
• 29. Martinelli I, Taioli E, Cetin I. Mutations in coagulation factors in women with unexplained late fetal loss. The New England Journal of Medicine; 2008; 343(14): 1015-1018. https://doi.org/10.1056/NEJM200010053431405
• 30. Younis J, Brenner B, Ohel G, Tal J, Lanir N, Ben-Ami M. Activated protein C resistance and factor V Leiden mutation can be associated with first – as well as second - trimester recurrent pregnancy loss. American Journal of Reproductive Immunology. 2000; 43(1): 31-35. https://doi.org/10.1111/j.8755-8920.2000.430106.x
• 31. Rajewski P, Książkiewicz B. [Cerebral venous and sinus thrombosis]. Udar Mózgu. 2010; 12(1-2): 47-50 (in Polish).
• 32. Gerhardt A, Scharf RE, Beckmann MW, Struve S, Bender HG, Pillny M. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. The New England Journal of Medicine. 2000; 342(6): 374-80. https://doi.org/10.1056/NEJM200002103420602
• 33. Zotz RB, Gerhardt A, Scharf RE. Inherited thrombophilia and gestational venous thromboembolism. Best Practice Research Clinical Haematology. 2003; 16(2): 243-259. https://doi.org/10.1016/s1521-6926(03)00022-7
• 34. Mousa HA, Alfirević Z. Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome?. Human Reproduction. 2000; 15(8): 1830-1833.
• 35. Dekker JW, Lind J, Bloemenkamp KWM, Quint WGV, Kuijpers JC, Dorn LJ, et al. Inherited risk of thrombosis of the fetus and intrauterine fetal death. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2004; 117(1): 45-48.
• 36. Bartoszewicz L, Kalicki B, Jung A, Żuber J, Rustecka A. [Venous thromboembolism in children – risk factors, prophylaxis and treatment]. Pediatria i Medycyna Rodzinna. 2010; 6(2): 100-105 (in Polish).
• 37. Gerotziafas GT. Risk factors for venous thromboembolism in children. International Angiology. 2004; 23(3): 195-205.
• 38. Nowak-Göttl U, Kurnk K, Krümpel A, Stoll M. Thrombophilia in the young. Thrombosis and Haemostasis. 2008; 28(1-2): 16-20.
• 39. Chalmers E, Ganesen V, Liesner R. Guideline on the investigation, management and prevention of venous thrombosis in children. British Journal of Haematology. 2011; 154: 196. https://doi.org/10.1111/j.1365-2141.2010.08543.x
• 40. Smalisz-Skrzypczyk K, Klukowska K, Pawelec K, Matysiak M. [The analysis of the cause of thromboembolism in children]. Postępy Nauk Medycznych. 2013; 9: 640-645 (in Polish).

Identyfikatory

DOI

10.5114/hpc.2020.94719